Albert Bourla, AP Images

Pfiz­er re­veals de­lays across the board for its clin­i­cal gene ther­a­py pro­grams

At JP Mor­gan 2020, a year af­ter tak­ing the reins at Pfiz­er, Al­bert Bourla claimed the com­pa­ny was poised to be­come a leader in gene ther­a­py. He’s since thrown hun­dreds of mil­lions of dol­lars at those plans, in­clud­ing a $630 mil­lion deal just last month for two of Voy­ager’s AAVs.

Now, it ap­pears Phase III read­outs are fur­ther away than Bourla had hoped.

Set­backs have re­sult­ed in de­lays across all three of Pfiz­er’s clin­i­cal gene ther­a­py pro­grams, the com­pa­ny re­vealed in its Q3 re­sults on Tues­day — in­clud­ing one tri­al which was paused over safe­ty con­cerns.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.